Emily R Hankosky

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Glycemic Control

Electronic Health Record

Top Venues

Diabetes, obesity & metabolism

PharmacoEconomics

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Emily R Hankosky, Hui Wang, Lisa M Neff, Hong Kan, Fangyu Wang, Nadia N Ahmad, Adam Stefanski, W Timothy Garvey
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial. Diabetes, obesity & metabolism (2023)
Emily R Hankosky, Hui Wang, Lisa M Neff, Hong Kan, Fangyu Wang, Nadia N Ahmad, Ryan Griffin, Adam Stefanski, W Timothy Garvey
Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. Diabetes, obesity & metabolism (2023)
Emily R Hankosky, Michelle L Katz, Ludi Fan, Dongju Liu, Chanadda Chinthammit, Alan J M Brnabic, Elizabeth L Eby
Predictors of insulin pump initiation among people with type 2 diabetes from a US claims database using machine learning. Current medical research and opinion (2023)
Ágnes Benedict, Emily R Hankosky, Kinga Marczell, Jieling Chen, David J Klein, J Jaime Caro, Jay P Bae, Brian D Benneyworth
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes. PharmacoEconomics 40 (8) (2022)